|
|
|
Insider
Information: |
Enright Patrick G |
Relationship: |
10% Owner |
City: |
Burlingame |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
16 |
|
Direct
Shares |
3,308,185 |
|
Indirect Shares
|
27,432,603 |
|
|
Direct
Value |
$9,214,125 |
|
|
Indirect Value
|
$114,850,875 |
|
|
Total
Shares |
30,740,788 |
|
|
Total
Value |
$124,065,000 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
6
|
1
|
Stock
price went up :
|
5
|
1
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
5.0
|
1.0
|
Percentage
Gain/Loss : |
95.0%
|
101.2%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Molecular Templates, Inc. |
MTEM |
Director |
2006-04-20 |
496 |
2007-03-01 |
0 |
Premium* |
|
Sequenom Inc |
SQNM |
Director |
2006-12-07 |
771 |
2006-12-07 |
3,333,333 |
Premium* |
|
Corcept Therapeutics Inc |
CORT |
Director |
2017-03-16 |
272,281 |
2017-03-16 |
114,675 |
Premium* |
|
Jazz Pharmaceuticals Inc |
JAZZ |
Director |
2023-08-14 |
20,946 |
2022-08-08 |
2,000 |
Premium* |
|
Esperion Therapeutics, Inc. |
ESPR |
Director |
2013-07-01 |
0 |
2015-03-19 |
18,361 |
Premium* |
|
Collegium Pharmaceutical, Inc |
COLL |
10% Owner |
2015-05-12 |
0 |
2015-05-12 |
65,270 |
Premium* |
|
Aimmune Therapeutics, Inc. |
AIMT |
Director |
2020-10-13 |
0 |
2020-10-10 |
0 |
Premium* |
|
Aptinyx Inc. |
APTX |
Director |
2020-01-10 |
95,000 |
2020-01-10 |
3,356,746 |
Premium* |
|
Tricida, Inc. |
TCDA |
|
2018-07-02 |
0 |
2018-07-02 |
3,019,734 |
Premium* |
|
Venus Concept Inc |
VERO |
10% Owner |
|
0 |
2019-11-07 |
3,666,119 |
Premium* |
|
89bio, Inc. |
ETNB |
10% Owner |
2019-11-11 |
0 |
2020-11-16 |
891 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
10% Owner |
2020-01-29 |
0 |
2022-01-25 |
1,964,771 |
Premium* |
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2020-07-28 |
0 |
2022-04-19 |
4,174,379 |
Premium* |
|
Eargo, Inc. |
EAR |
10% Owner |
2021-04-14 |
2,918,691 |
2021-04-14 |
5,012 |
Premium* |
|
Vera Therapeutics, Inc. |
VERA |
Director, 10% Owner |
2021-05-18 |
0 |
2023-02-06 |
5,144,212 |
Premium* |
|
Lexeo Therapeutics, Inc. |
LXEO |
10% Owner |
2023-11-07 |
0 |
2023-11-07 |
2,567,100 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
169 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
MTEM |
Molecular Templates, Inc. |
See Footnote 1 |
|
2005-02-09 |
4 |
B |
$7.00 |
$1,692,033 |
I/I |
241,719 |
0 |
2.1 |
- |
|
MTEM |
Molecular Templates, Inc. |
See Footnote 1 |
|
2005-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
3,312,006 |
3,553,725 |
|
- |
|
MTEM |
Molecular Templates, Inc. |
See Footnote 1 |
|
2005-10-28 |
4 |
S |
$10.46 |
$596,251 |
I/I |
(57,003) |
3,496,722 |
|
- |
|
MTEM |
Molecular Templates, Inc. |
See Footnote 1 |
|
2006-03-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,165,574) |
2,331,148 |
|
- |
|
MTEM |
Molecular Templates, Inc. |
Director |
|
2006-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
248 |
248 |
|
- |
|
MTEM |
Molecular Templates, Inc. |
Director |
|
2006-04-20 |
4 |
A |
$0.00 |
$0 |
D/D |
248 |
496 |
|
- |
|
MTEM |
Molecular Templates, Inc. |
See Footnote 1 |
|
2006-04-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,165,574) |
1,165,574 |
|
- |
|
SQNM |
Sequenom Inc |
See Footnote 1 |
|
2006-12-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,333,333) |
3,333,333 |
0 |
- |
|
SQNM |
Sequenom Inc |
Director |
|
2006-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
771 |
771 |
0 |
- |
|
MTEM |
Molecular Templates, Inc. |
See Footnote 1 |
|
2007-02-28 |
4 |
S |
$1.49 |
$1,137,173 |
I/I |
(750,000) |
415,574 |
0 |
- |
|
MTEM |
Molecular Templates, Inc. |
See Footnote 1 |
|
2007-03-01 |
4 |
S |
$1.45 |
$606,361 |
I/I |
(415,574) |
0 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2008-11-11 |
4 |
A |
$1.45 |
$506,666 |
I/I |
349,425 |
3,879,875 |
0 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2009-02-06 |
4 |
B |
$0.69 |
$3,189,643 |
I/I |
4,642,857 |
8,522,732 |
2.25 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
Director |
|
2009-07-07 |
4 |
A |
$3.63 |
$6,881,514 |
I/I |
1,895,734 |
37,248 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
Director |
|
2009-09-01 |
4 |
B |
$7.21 |
$556,007 |
I/I |
77,100 |
38,763 |
2.1 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
Director |
|
2009-09-02 |
4 |
B |
$7.22 |
$526,309 |
I/I |
72,900 |
40,195 |
2.1 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2009-10-16 |
4 |
B |
$1.38 |
$3,377,623 |
I/I |
2,447,553 |
10,970,285 |
2.25 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2010-04-21 |
4 |
OE |
$1.66 |
$1,422,029 |
I/I |
856,644 |
11,826,929 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
Director |
|
2010-05-11 |
4 |
B |
$8.35 |
$6,999,997 |
I/I |
838,323 |
56,667 |
2.1 |
- |
|
CORT |
Corcept Therapeutics Inc |
Director |
|
2011-01-21 |
4 |
B |
$3.90 |
$2,925,000 |
I/I |
750,000 |
12,576,929 |
2.25 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
Director |
|
2012-01-11 |
4 |
OE |
$4.21 |
$729,850 |
D/D |
65,000 |
58,984 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
Director |
|
2012-01-11 |
4 |
D |
$48.60 |
$729,729 |
D/D |
(15,015) |
49,985 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
Director |
|
2012-01-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(49,985) |
0 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
Director |
|
2012-01-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,884,057) |
0 |
0 |
- |
|
JAZZ |
Jazz Pharmaceuticals Inc |
Director |
|
2012-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
49,985 |
49,985 |
0 |
- |
|
169 Records found
|
|
Page 1 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|